Early BCG vaccination is unrelated to pulmonary immunity against Mycobacterium tuberculosis in adults

To the Editor: Vaccination with Mycobacterium bovis bacille Calmette–Guerin (BCG) is performed for the prevention of tuberculosis. M. bovis BCG vaccination is among the most commonly applied of all vaccines worldwide [1]. M. bovis BCG vaccination efficiently reduces the morbidity and mortality of tuberculosis in children, especially miliary tuberculosis and meningitis [2]. Although recent investigations of Mycobacterium tuberculosis -specific immune responses by interferon-γ release assays (IGRAs) provide evidence on the effect of M. bovis BCG vaccination on the prevention of primary infection with M. tuberculosis [3–5], it has been suggested that this effect diminishes during adolescence [2, 6]. Consequently, adults are probably not protected from pulmonary tuberculosis by BCG vaccination. To date, no study has investigated the impact of M. bovis BCG vaccination performed in childhood on pulmonary immune responses in adults. The objective of this study was to assess the effect of childhood M. bovis BCG vaccination on systemic and pulmonary immune responses to M. tuberculosis in healthy adult individuals exposed to patients with acid-fast bacilli (AFB)-positive sputum smear-positive tuberculosis in Germany. An observational, cross-sectional, multicentre study was conducted by the German Ministry of Education and Research-funded research consortium on “Pulmonary Tuberculosis – Host and Pathogen Determinants of Resistance and Disease Progression (TB or Not TB)”. Healthcare workers (HCWs) with 1) ongoing professional contact with patients with AFB sputum smear-positive tuberculosis, 2) a cumulative professional exposure of at least 2 years, and 3) no clinical signs and/or symptoms of active tuberculosis were recruited at 18 German pulmonary medicine centres (centres are listed in the Acknowledgements section). Furthermore, household contacts (HHCs) without evidence of active tuberculosis were enrolled at three urban municipal healthcare centres ( i.e. Frankfurt, Hamburg and Hannover); their enrolment required 1) the absence of clinical signs and/or …

[1]  M. Tameris,et al.  The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses , 2014, PloS one.

[2]  P. Whiting,et al.  Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. , 2013, Health technology assessment.

[3]  N. Range,et al.  BCG protects against tuberculosis irrespective of HIV status: a matched case-control study in Mwanza, Tanzania , 2012, Thorax.

[4]  R. Basu Roy,et al.  Current understanding of the immune response to tuberculosis in children , 2012, Current opinion in infectious diseases.

[5]  W. Haas,et al.  [New recommendations for contact tracing in tuberculosis]. , 2011, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[6]  I. Abubakar,et al.  Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  M. Mcevoy,et al.  BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. , 2009, Vaccine.

[8]  Manfred Wagner,et al.  Empfehlungen zur Sicherung der Qualität in der Bronchoskopie , 2004 .

[9]  Global routine vaccination coverage, 2011. , 2012, MMWR. Morbidity and mortality weekly report.

[10]  N. Mülleneisen [New recommendations for contact tracing in tuberculosis]. , 2011, Pneumologie.

[11]  M. Wagner,et al.  [Recommendations for quality standards in bronchoscopy]. , 2004, Pneumologie.